These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16500908)

  • 1. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors.
    Richly H; Henning BF; Kupsch P; Passarge K; Grubert M; Hilger RA; Christensen O; Brendel E; Schwartz B; Ludwig M; Flashar C; Voigtmann R; Scheulen ME; Seeber S; Strumberg D
    Ann Oncol; 2006 May; 17(5):866-73. PubMed ID: 16500908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.
    Kupsch P; Henning BF; Passarge K; Richly H; Wiesemann K; Hilger RA; Scheulen ME; Christensen O; Brendel E; Schwartz B; Hofstra E; Voigtmann R; Seeber S; Strumberg D
    Clin Colorectal Cancer; 2005 Sep; 5(3):188-96. PubMed ID: 16197622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
    Mross K; Steinbild S; Baas F; Gmehling D; Radtke M; Voliotis D; Brendel E; Christensen O; Unger C
    Eur J Cancer; 2007 Jan; 43(1):55-63. PubMed ID: 17095207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
    Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
    Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
    Awada A; Gil T; Whenham N; Van Hamme J; Besse-Hammer T; Brendel E; Delesen H; Joosten MC; Lathia CD; Loembé BA; Piccart-Ghebart M; Hendlisz A
    J Clin Pharmacol; 2011 Dec; 51(12):1674-84. PubMed ID: 21209247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
    Moore M; Hirte HW; Siu L; Oza A; Hotte SJ; Petrenciuc O; Cihon F; Lathia C; Schwartz B
    Ann Oncol; 2005 Oct; 16(10):1688-94. PubMed ID: 16006586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
    Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
    Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
    Azad NS; Posadas EM; Kwitkowski VE; Steinberg SM; Jain L; Annunziata CM; Minasian L; Sarosy G; Kotz HL; Premkumar A; Cao L; McNally D; Chow C; Chen HX; Wright JJ; Figg WD; Kohn EC
    J Clin Oncol; 2008 Aug; 26(22):3709-14. PubMed ID: 18669456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.
    Awada A; Hendlisz A; Christensen O; Lathia CD; Bartholomeus S; Lebrun F; de Valeriola D; Brendel E; Radtke M; Delaunoit T; Piccart-Gebhart M; Gil T
    Eur J Cancer; 2012 Mar; 48(4):465-74. PubMed ID: 22285181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.
    Minami H; Kawada K; Ebi H; Kitagawa K; Kim YI; Araki K; Mukai H; Tahara M; Nakajima H; Nakajima K
    Cancer Sci; 2008 Jul; 99(7):1492-8. PubMed ID: 18477034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.
    Desar IM; Timmer-Bonte JN; Burger DM; van der Graaf WT; van Herpen CM
    Br J Cancer; 2010 Nov; 103(11):1637-43. PubMed ID: 21045832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
    Infante JR; Jones SF; Bendell JC; Greco FA; Yardley DA; Lane CM; Spigel DR; Hainsworth JD; Burris HA
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):137-44. PubMed ID: 21626051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
    Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
    Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
    Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
    Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial.
    Richly H; Schultheis B; Adamietz IA; Kupsch P; Grubert M; Hilger RA; Ludwig M; Brendel E; Christensen O; Strumberg D
    Eur J Cancer; 2009 Mar; 45(4):579-87. PubMed ID: 19101137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium.
    Welch SA; Hirte HW; Elit L; Schilder RJ; Wang L; Macalpine K; Wright JJ; Oza AM
    Int J Gynecol Cancer; 2010 Jul; 20(5):787-93. PubMed ID: 20847613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
    Flaherty KT; Schiller J; Schuchter LM; Liu G; Tuveson DA; Redlinger M; Lathia C; Xia C; Petrenciuc O; Hingorani SR; Jacobetz MA; Van Belle PA; Elder D; Brose MS; Weber BL; Albertini MR; O'Dwyer PJ
    Clin Cancer Res; 2008 Aug; 14(15):4836-42. PubMed ID: 18676756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
    Puzanov I; Sosman J; Santoro A; Saif MW; Goff L; Dy GK; Zucali P; Means-Powell JA; Ma WW; Simonelli M; Martell R; Chai F; Lamar M; Savage RE; Schwartz B; Adjei AA
    Invest New Drugs; 2015 Feb; 33(1):159-68. PubMed ID: 25294187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.
    Richly H; Kupsch P; Passage K; Grubert M; Hilger RA; Kredtke S; Voliotis D; Scheulen ME; Seeber S; Strumberg D
    Int J Clin Pharmacol Ther; 2003 Dec; 41(12):620-1. PubMed ID: 14692720
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.
    Schultheis B; Kummer G; Zeth M; Brendel E; Xia C; Kornacker M; Strumberg D
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):333-9. PubMed ID: 21735354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.